CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy
Authors
Jennifer L. Brogdon (ORCID: https://orcid.org/0000-0002-2084-832X)
Carl H. June (ORCID: https://orcid.org/0000-0003-0241-3557)
Lisa Wray (ORCID: https://orcid.org/0000-0003-0012-9739)
Susan McClory (ORCID: https://orcid.org/0000-0002-4607-5230)
Yimei Li (ORCID: https://orcid.org/0000-0001-9067-6992)
CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy
Jennifer L. Brogdon, Carl H. June, Lisa Wray, Susan McClory et al.
Citations
13 citations
Journal
Journal for ImmunoTherapy of Cancer
Topics
CAR-T cell therapy research
Field-Weighted Citation Impact (FWCI)
13.59
article
CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy
Jennifer L. Brogdon, Carl H. June, Lisa Wray, Susan McClory, Yimei Li, Gabriela Plesa, Susan R. Rheingold, Boris Engels, Vanessa Gonzalez, Joseph A. Fraietta, Richard Aplenc, Allison Barz Leahy, Shannon L. Maude, Caroline Diorio, Amanda M. DiNofia, Laura K. Shinehouse, Emma Iannone, Stephan A. Grupp, Colleen Callahan, Julie K. Jadlowsky, Diane Baniewicz, Marco Ruella, Gerald Wertheim, Regina M. Myers, Noelle V. Frey, Elizabeth Olson Hexner, Hongyan Liu, Donald L. Siegel, Clare Taylor
article en
13 citations
Abstract
No abstract available for this paper.
Publication Tag
Journal for ImmunoTherapy of CancerVol. 13(4)
Institutions
Children's Hospital of Philadelphia (US), Miltenyi Biotec (Germany) (DE), Parker Institute for Cancer Immunotherapy (US), Novartis (United States) (US), University of Pennsylvania (US), University of Colorado Denver (US)
Funders
American Society of Hematology, Curing Kids Cancer, National Cancer Institute